Vor Bio up as initial data from blood cancer study shows promise

Vor Biopharma

07/12/2022 13:53

** Shares of Vor Bio  VOR.O  rise 13.9% to $4.9 before the
bell
    ** The drug developer says initial data from
early-to-mid-stage study of its experimental therapy to treat
patients with a type of blood cancer was well-tolerated
 urn:newsml:reuters.com:*:nGNX2tP23x
    ** Blood count was successfully maintained in the first
patient after the transplant treatment - VOR 
    ** Co says the study continues to enroll patients and
additional data is expected in 2023
    ** Up to Tuesday's close, stock down ~63% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))